title: The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
abstract: Evidence is now available showing that cyclooxygenase (COX)-2, which is involved in prostaglandin production, is overexpressed in many types of tumors including breast. Several reports have indicated that HER-2/neu-positive breast tumors are associated with an increased amount of COX-2 protein. In this study, we evaluated the effectiveness of the select COX-1 and COX-2 inhibitors in preventing mammary tumor development in HER-2/neu transgenic mice. At 4 weeks of age, female HER-2/neu mice were fed a #5020 rodent diet supplemented with 900 ppm celecoxib, a COX-2 inhibitor, 64 ppm of SC560, a COX-1 inhibitor, or the unsupplemented #5001 diet (control). The incidence of mammary tumors was significantly lower in the celecoxib-fed mice (71%; P = 0.001 versus control) than in the control mice (95%) or in the SC560-fed mice (91%). Celecoxib-treated mice also developed fewer tumors (1.3 +/- 1.1 SD; P = 0.039 versus control) than the control mice (2.2 +/- 1.2) or the SC560 treated mice (2.3 +/- 1.3). The median time to tumor development was 266 days in the control group versus 291 days in the celecoxib-treated group (P = 0.003 versus control). Lung metastasis was also reduced by treatment with celecoxib. The COX-1 inhibitor SC560 had no protective effect. The protection offered by celecoxib was associated with significantly lower concentrations of prostacyclin and prostaglandin E(2) in mammary tumors and their adjacent mammary glands. Our findings provide additional preclinical evidence to support the clinical studies to investigate the potential effectiveness of COX-2 inhibitors in protecting woman who are at high risk for breast cancer.
authors.affiliation: Department of Surgery, Jefferson Medical College, Philadelphia, Pennsylvania 19107, USA. Susan.Lanza-Jacoby@mail.tju.edu
authors.forename: Susan
authors.initials: S
authors.lastname: Lanza-Jacoby
authors.forename: Sheldon
authors.initials: S
authors.lastname: Miller
authors.forename: John
authors.initials: J
authors.lastname: Flynn
authors.forename: Kathleen
authors.initials: K
authors.lastname: Gallatig
authors.forename: Constantine
authors.initials: C
authors.lastname: Daskalakis
authors.forename: Jaime L
authors.initials: JL
authors.lastname: Masferrer
authors.forename: Ben S
authors.initials: BS
authors.lastname: Zweifel
authors.forename: Harjeet
authors.initials: H
authors.lastname: Sembhi
authors.forename: Irma H
authors.initials: IH
authors.lastname: Russo
mesh_terms: D000818:Animals; D001707:Biopsy, Needle; D015153:Blotting, Western; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D004195:Disease Models, Animal; D005260:Female; D018734:Genes, erbB-2 / Q000187:drug effects* / Q000235:genetics; D007150:Immunohistochemistry; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008822:Mice, Transgenic; D011720:Pyrazoles; D012680:Sensitivity and Specificity; D013449:Sulfonamides / Q000494:pharmacology*
chemical_list: D016861:Cyclooxygenase Inhibitors; D011720:Pyrazoles; D013449:Sulfonamides; D000068579:Celecoxib